Photodynamic Therapy of Tumors Can Lead to Development of Systemic Antigen-Specific Immune Response
Figure 5
Immunohistochemical staining for LAMP-1 (CD107a) of CT26.CL25 tumors.
A. non-treated control. B. negative control for staining. C. CT26.CL25 PDT treated tumors day 5. D. CT26.CL25 non-treated, contralateral tumors day 5. E. CT26.CL25 PDT treated tumors day 16. F. CT26.CL25 non-treated, contralateral tumors day 16. Analysis of β-gal antigen expression and loss by X-gal staining. G. CT26WT control tumors negative for β-gal antigen, H. CT26.CL25 non-treated control tumors which show robust blue positive staining for β-gal antigen. I. CT26.CL25 non-treated, contralateral tumors that escaped immune surveillance and continued to grow. They show significantly decreased staining for β-gal antigen.